News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accium BioSciences, Inc. And Quintiles Transnational Corp. Establish Strategic Partnership For Microdosing And Information-Rich(TM) Phase I Trials


5/24/2006 12:56:29 PM

SEATTLE--(BUSINESS WIRE)--May 23, 2006--Accium BioSciences, Inc., (Accium) the first fully-commercial Accelerator Mass Spectrometry (AMS) analytical facility in the U.S., and Quintiles Transnational Corp., the world's leading pharmaceutical services company, today announced the establishment of a partnership to offer turnkey Exploratory-IND, Microdosing and Information-Rich(TM) Phase I clinical trials services to biopharmaceutical researchers. Accium's Accelerator Mass Spectrometer-based study design expertise and core bioanalytical capabilities combined with the clinical development and regulatory experience and expertise of Quintiles delivers a seamless solution to the critical decision process in early drug development.

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES